Ji Yeoun Yoo, MD
Assistant Professor AdjunctAbout
Research
Publications
2025
The thalamus: Structure, function, and neurotherapeutics
Marcuse L, Langan M, Hof P, Panov F, Saez I, Jimenez-Shahed J, Figee M, Mayberg H, Yoo J, Ghatan S, Balchandani P, Fields M. The thalamus: Structure, function, and neurotherapeutics. Neurotherapeutics 2025, 22: e00550. PMID: 39956708, DOI: 10.1016/j.neurot.2025.e00550.Peer-Reviewed Original ResearchNew onset refractory status epilepticus: Long‐term outcomes beyond seizures
Espino P, Eschbach K, Blank L, Cervenka M, Muscal E, Farias‐Moeller R, Gilmore E, Gopaul M, Haider H, Hanin A, Hirsch L, Kellogg M, Kluger G, Lee S, Melendez‐Zaidi A, Navarro V, Oliger A, Pasini E, Reuner G, Sharpe C, Sheikh Z, Steigleder L, Steriade C, Stredny C, Strzelczyk A, Taraschenko O, van Baalen A, Vinette S, Wickström R, Wong N, Yoo J, Gofton T. New onset refractory status epilepticus: Long‐term outcomes beyond seizures. Epilepsia 2025 PMID: 39825688, DOI: 10.1111/epi.18267.Peer-Reviewed Original ResearchQuality of lifeLong-term outcomesCaregiver burdenConsensus-building processDevelopment of targeted management strategiesWorking GroupOutcome domainsLong-term mortalityOutcome measuresConsensus processExpert panelRecovery trajectoriesSurvivorsOutcomesPubMed searchResearch studiesKnowledge gapsCaregiversStandard dataPsychiatric
2024
Trends in management of patients with new‐onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis
Hanin A, Jimenez A, Gopaul M, Asbell H, Aydemir S, Basha M, Batra A, Damien C, Day G, Eka O, Eschbach K, Fatima S, Fields M, Foreman B, Gerard E, Gofton T, Haider H, Hantus S, Hocker S, Jongeling A, Aparicio M, Kandula P, Kang P, Kazazian K, Kellogg M, Kim M, Lee J, Marcuse L, McGraw C, Mohamed W, Orozco J, Pimentel C, Punia V, Ramirez A, Steriade C, Struck A, Taraschenko O, Treister A, Wainwright M, Yoo J, Zafar S, Zhou D, Zutshi D, Gaspard N, Hirsch L. Trends in management of patients with new‐onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis. Epilepsia 2024, 65: e148-e155. PMID: 38837761, DOI: 10.1111/epi.18014.Peer-Reviewed Original ResearchNew-onset refractory status epilepticusSecond-line immunotherapyKetogenic dietStatus epilepticusDuration of status epilepticusRefractory status epilepticusStatus epilepticus onsetManagement of patientsEvolving treatment landscapeTreatment landscapeImmunotherapyConsensus recommendationsInterim analysisPatientsPatient outcomesAnakinraEpilepticusShort durationMedianORCIDietDaysTocilizumabIncreased useComparative analysis of patients with new onset refractory status epilepticus preceded by fever (febrile infection‐related epilepsy syndrome) versus without prior fever: An interim analysis
Jimenez A, Gopaul M, Asbell H, Aydemir S, Basha M, Batra A, Damien C, Day G, Eka O, Eschbach K, Fatima S, Fields M, Foreman B, Gerard E, Gofton T, Haider H, Hantus S, Hocker S, Jongeling A, Aparicio M, Kandula P, Kang P, Kazazian K, Kellogg M, Kim M, Lee J, Marcuse L, McGraw C, Mohamed W, Orozco J, Pimentel C, Punia V, Ramirez A, Steriade C, Struck A, Taraschenko O, Treister A, Yoo J, Zafar S, Zhou D, Zutshi D, Gaspard N, Hirsch L, Hanin A. Comparative analysis of patients with new onset refractory status epilepticus preceded by fever (febrile infection‐related epilepsy syndrome) versus without prior fever: An interim analysis. Epilepsia 2024, 65: e87-e96. PMID: 38625055, DOI: 10.1111/epi.17988.Peer-Reviewed Original ResearchFebrile infection-related epilepsy syndromeRefractory status epilepticusMacrophage inflammatory protein-1 alphaOnset refractory status epilepticusStatus epilepticusCerebrospinal fluidFIRES patientsCerebrospinal fluid interleukin-6Magnetic resonance imaging findingsComparative analysis of patientsAnalysis of patientsChemokine ligand 2Presenting symptomsFebrile infectionsClinical featuresGastrointestinal prodromeImaging findingsInflammatory biomarkersAntiseizure medicationsInterleukin-6Epilepsy syndromesInterim analysisPatientsEpilepticusFeverElevated phase amplitude coupling as a depression biomarker in epilepsy
Young J, Chan A, Jette N, Bender H, Saad A, Saez I, Panov F, Ghatan S, Yoo J, Singh A, Fields M, Marcuse L, Mayberg H. Elevated phase amplitude coupling as a depression biomarker in epilepsy. Epilepsy & Behavior 2024, 152: 109659. PMID: 38301454, PMCID: PMC10923038, DOI: 10.1016/j.yebeh.2024.109659.Peer-Reviewed Original ResearchBeck Depression Inventory-IIPhase-amplitude couplingComorbid depressionAssessment of depressive symptomsBeck Depression Inventory-II scoresAssociated with comorbid depressionAnterior cingulate cortexEpilepsy patientsAmplitude couplingPre-operative assessmentElevated phase-amplitude couplingSpectral powerOrbitofrontal cortexCingulate cortexPrimary depressionCase-control comparisonDepressive symptomsBrain regionsBrain activityDepression biomarkersAdult epilepsy patientsDepressionBrain recordingsPatient studiesTreatment targetProvider Experience With the Use of Ketamine for Refractory Status Epilepticus
Tantillo G, Davis N, Granstein J, Yoo J, Agarwal P, Reilly K, Reynolds A, Kayal G, Liang J, Jetté N. Provider Experience With the Use of Ketamine for Refractory Status Epilepticus. Clinical Neuropharmacology 2024, 47: 37-43. PMID: 38478363, DOI: 10.1097/wnf.0000000000000582.Peer-Reviewed Original ResearchConceptsRefractory status epilepticusStatus epilepticusPerceived contraindicationsUse of vasopressorsFirst-line agentsRefractory status epilepticus treatmentSecond-line agentsAssociated with complicationsElevated intracranial pressureNeurocritical Care SocietyRespiratory depressionHeart failureEEG monitoringHemodynamic supportOptimal doseKetamine useSeizure controlIntracranial pressureControl seizuresDecreased needKetamine usersAmerican Epilepsy SocietyKetamineAmerican AcademyAnesthetic agentsHealth care access, psychosocial outcomes and mental health in adults living with epilepsy during the COVID-19 pandemic
Mc Carthy L, Mathew B, Blank L, Van Hyfte G, Gotlieb E, Goldstein J, Agarwal P, Kwon C, Singh A, Fields M, Marcuse L, Yoo J, Sivarak E, Gururangan K, Navis A, Jetté N. Health care access, psychosocial outcomes and mental health in adults living with epilepsy during the COVID-19 pandemic. Epilepsy & Behavior 2024, 151: 109617. PMID: 38219607, DOI: 10.1016/j.yebeh.2023.109617.Peer-Reviewed Original ResearchConceptsPatient Health Questionnaire-9Generalized Anxiety Disorder-7Psychosocial outcomesMental healthHealthcare accessCancelled visitsCross-sectional study of adultsHealth care accessCOVID-19 pandemicMental health comorbiditiesPoor mental healthSocial support issuesPoor psychosocial outcomesSymptoms of anxietyCross-sectional studyStudy of adultsCare accessPsychosocial supportHealth comorbiditiesModerate/severe depressionHealth systemTelehealth visitsNeurological carePLWEStandardized questionnaire
2021
Analysis of Brief Potentially Ictal Rhythmic Discharges (BIRDs) and seizures in Epilepsy Patients with Responsive Neurostimulation undergoing Scalp Electroencephalography (2982)
Lemus H, Jette N, Fields M, Bolden D, Yoo J. Analysis of Brief Potentially Ictal Rhythmic Discharges (BIRDs) and seizures in Epilepsy Patients with Responsive Neurostimulation undergoing Scalp Electroencephalography (2982). Neurology 2021, 96 DOI: 10.1212/wnl.96.15_supplement.2982.Peer-Reviewed Original Research
2020
The Effects of Paternal Seizure Disorders and Antiseizure Medication Use on Offspring Neurodevelopmental Outcomes, Psychiatric Comorbidities, and Sexual Health. (4262)
Esquivel H, Casale M, Young J, Marcuse L, Yoo J, Mueller B, Fields M. The Effects of Paternal Seizure Disorders and Antiseizure Medication Use on Offspring Neurodevelopmental Outcomes, Psychiatric Comorbidities, and Sexual Health. (4262). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.4262.Peer-Reviewed Original Research
2019
Early Use of Vagal Nerve Stimulation (VNS) in a Patient with New Onset Refractory Status Epilepticus (NORSE) (P5.5-032)
Wong B, Yoo J, Fields M. Early Use of Vagal Nerve Stimulation (VNS) in a Patient with New Onset Refractory Status Epilepticus (NORSE) (P5.5-032). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.p5.5-032.Peer-Reviewed Original Research
Get In Touch
Contacts
Email